Company profile: NorthStar Medical Radioisotopes
1.1 - Company Overview
Company description
- Provider of radioisotopes and radiopharmaceutical CDMO/CMO services for the nuclear medicine market, producing Actinium-225 (Ac-225) and Copper-67 (Cu-67) in scalable, commercial quantities via electron beam accelerators, and delivering end-to-end contract development and manufacturing from research to commercialization, with environmentally friendly accelerator-based production of multiple isotopes.
Products and services
- Radiopharmaceutical CDMO/CMO Services: NorthStar offers contract development and manufacturing services for radiopharmaceuticals, delivering full-lifecycle support from research to commercialization
- Actinium-225 (Ac-225): NorthStar produces Ac-225 using electron beam accelerators, supplying scalable and reliable quantities for cancer therapy
- Copper-67 (Cu-67): NorthStar produces Cu-67 from Zinc-68 using electron beam accelerators, offering commercial-scale quantities for therapeutic use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NorthStar Medical Radioisotopes
Elegen
HQ: United States
Website
- Description: Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elegen company profile →
Eleva Biologics
HQ: Germany
Website
- Description: Provider of novel biological therapies developed with pharmaceutical partners, leveraging a unique moss-based production platform to produce biologics such as antibodies, replacement enzymes, and fusion toxins; has advanced drug candidates into clinical phases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleva Biologics company profile →
Sloning Biotechnology
HQ: Germany
Website
- Description: Provider of tailored protein engineering solutions for industrial and biopharmaceutical sectors, leveraging the patented Slonomics technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability, and production cost on an industrial-scale robotic system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sloning Biotechnology company profile →
MicroLiquid
HQ: Spain
Website
- Description: Provider of contract development and manufacturing of polymer microfluidic disposable devices and life science microfluidic products for worldwide customers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MicroLiquid company profile →
Newport Labs
HQ: United States
Website
- Description: Provider of veterinary healthcare services and high-quality autogenous biologics for the livestock industry, applying 21st technology to a traditional autogenous approach to formulate products that pinpoint specific disease problems, supported by dedicated employees and innovative solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Newport Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NorthStar Medical Radioisotopes
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NorthStar Medical Radioisotopes
2.2 - Growth funds investing in similar companies to NorthStar Medical Radioisotopes
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NorthStar Medical Radioisotopes
4.2 - Public trading comparable groups for NorthStar Medical Radioisotopes
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →